EPB41L3

Across TCGA pan-cancer cohorts, EPB41L3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EPB41L3 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPB41L3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPB41L3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where EPB41L3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.623	0.297	<.001	43	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.019	36	view →
CCRCC	OS	Median	All	1.000	0.684	.011	10	view →
HNSC	DFS	Tertile	II,III,IV	0.877	1.000	.006	7	view →
LUAD	OS	Median	III,IV	0.230	0.624	.022	6	view →
UCEC	DFS	Tertile	II,III,IV	0.399	0.904	.018	4	view →
LSCC	OS	Tertile	II,III,IV	0.919	0.834	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EPB41L3–PDAC (DFS)

Open the PDAC breakdown →